CYP2C8, CYP2C9 , and CYP2C cluster
Ordering Recommendation
Use to assess genetic risk of abnormal drug metabolism for drugs metabolized by enzymes coded by CYP2C8, CYP2C9, and the 2C cluster variant (rs12777823).
May aid in drug selection and dose planning for drugs metabolized by enzymes coded by CYP2C8, CYP2C9 and the 2C cluster variant (rs12777823).
New York DOH Approval Status
Specimen Required
Lavender (EDTA), pink (K2EDTA), or yellow (ACD solution A or B).
Transport 3 mL whole blood. (Min: 1 mL)
Preferred transport temp: Refrigerated.
Plasma or serum. Specimens collected in sodium heparin or lithium heparin. Frozen specimens in glass collection tubes.
Counseling and informed consent are recommended for genetic testing. Consent forms are linked above.
New York Clients: Informed consent is required with submission.
Room temperature: 3 days; Refrigerated: 1 week; Frozen: 1 month
Methodology
Polymerase Chain Reaction (PCR) / Fluorescence Monitoring
Performed
Varies
Reported
5-10 days
Reference Interval
Refer to report
Interpretive Data
Refer to report
Laboratory Developed Test (LDT)
Note
Hotline History
CPT Codes
81227; 81479
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 2008931 | CYP2C9 Phenotype | 79716-7 |
| 3001502 | 2C8/2C9 Specimen | 66746-9 |
| 3001503 | CYP2C8 Genotype | 78972-7 |
| 3001504 | CYP2C9 Genotype | 46724-1 |
| 3001505 | 2C8/2C9 Interpretation | 50398-7 |
| 3004497 | CYP2C8 Phenotype | 81259-4 |
| 3004499 | CYP2C Cluster Geno | 101785-4 |
| 3004500 | CYP2C Cluster Pheno | 81259-4 |
| 3016871 | EER CYP2C8 CYP2C9 CYP2C Cluster | 11526-1 |
Aliases
- 2C8
- 2C9
- celecoxib
- Coumadin
- CYP2C8
- CYP2C9
- CYP2C9 cluster
- Cytochrome P450 2C8
- Cytochrome P450 2C9 Genotype
- flurbiprofen
- glibenclamide
- gliclazide
- glimepiride
- ibuprofen
- lornoxicam
- Mayzent
- meloxicam
- NSAIDS
- phenytoin
- piroxicam
- siponimod
- sulfonylureas
- tenoxicam
- tolbutamide
- warfarin
















